Like other GLP-1 products, the most common adverse event was gastrointestinal side effects (nausea, vomiting, diarrhea), which tended to decrease over time
It was first approved for the treatment of type 2 diabetes as a once-weekly injection (0.5 mg, 1 mg, or 2 mg) in 2017 (Ozempic) and as a once-daily oral pill (7 mg or 14 mg) in 2019 (Rybelsus)
Physician-led planning ensures balance, proportion, and natural outcomes
The next few months, and beyond, are shaping up to be a pivotal time for the GLP-1 landscape, as experts anticipate several new indication decisions from the United States (U.S.) Food and Drug Administration (FDA), including for metabolic dysfunction-associated steatohepatitis (MASH) and the first orally administered GLP-1 medicines for chronic weight management